As of 2024-12-14, the Intrinsic Value of Cosmo Pharmaceuticals NV (COPN.SW) is
31.44 CHF. This COPN.SW valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 60.30 CHF, the upside of Cosmo Pharmaceuticals NV is
-47.90%.
The range of the Intrinsic Value is 18.16 - 221.93 CHF
31.44 CHF
Intrinsic Value
COPN.SW Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
18.16 - 221.93 |
31.44 |
-47.9% |
| DCF (Growth 10y) |
22.17 - 271.49 |
38.47 |
-36.2% |
| DCF (EBITDA 5y) |
11.27 - 16.09 |
13.32 |
-77.9% |
| DCF (EBITDA 10y) |
13.76 - 20.08 |
16.41 |
-72.8% |
| Fair Value |
92.97 - 92.97 |
92.97 |
54.17% |
| P/E |
2.00 - 54.37 |
21.73 |
-64.0% |
| EV/EBITDA |
9.32 - 66.03 |
31.72 |
-47.4% |
| EPV |
14.77 - 22.24 |
18.51 |
-69.3% |
| DDM - Stable |
72.53 - 1,335.89 |
704.21 |
1067.8% |
| DDM - Multi |
9.78 - 143.96 |
18.53 |
-69.3% |
COPN.SW Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
1,057.66 |
| Beta |
0.72 |
| Outstanding shares (mil) |
17.54 |
| Enterprise Value (mil) |
1,007.88 |
| Market risk premium |
5.10% |
| Cost of Equity |
4.92% |
| Cost of Debt |
4.25% |
| WACC |
4.91% |